



CHEMCON
Speciality Chemicals Limited



CIN : U24231GJ1988PLC011652

November 09, 2020

Listing Compliance & Legal Regulatory
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 023

Listing & Compliance
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex,
Bandra East, Mumbai 400 051

Stock Code: **543233**

Stock Symbol: **CHEMCON**

Dear Sir/Madam,

Sub: Press Release -Unaudited Financial Results of the company for the quarter ended 30th September, 2020.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is a press release being issued by the Company on the captioned subject, the content of which is self-explanatory.

This is for your information and records.

Thanking you,

Yours faithfully
For Chemcon Speciality Chemicals Limited


Shahilkumar Kapatel
Company Secretary & Compliance Officer
Membership No.: A52211



Corporate Office : 9th Floor, Onyx Business Center, Akshar Chowk, Old Padra Road, Vadodara - 390 020. INDIA Tel.: +91 265 2981195/2983754, Fax: +91 265 2983754 Email : info@cscpl.com

Regd. Office : Block No. 355-357, Manjusar - Kunpad Road, Village: Manjusar, Taluka: Savli, Dist.: Vadodara - 391 775. INDIA Tel.: +91 2667 264104


Website: www.cscpl.com

Q2FY21 Financial Highlights


- Revenue Stood at Rs 61.5 Cr
- EBITDA at Rs 23.3 Cr, growth of 19.3% on YoY basis
- PAT at Rs 15.6 Cr, growth of 14.4% on YoY basis

Vadodara, November 9th, 2020: Chemcon Speciality Chemicals Limited, a leading manufacturer of specialized chemicals, such as Hexamethyldisilazane (“HMDS”), Chloromethyl Isopropyl Carbonate (“CMIC”) and inorganic bromides, announced its un-audited financial results for the quarter and half year ended on September 30, 2020.


Financial and Operational Highlights




Geographic-Wise (%)




Business-wise (%)



Total Volume (MT)



Segment Volume (MT)



Commenting on the results, Mr. Kamal Aggarwal, Chairman & MD said, “ We are delighted to see such an overwhelming response for our IPO. We welcome new shareholders & congratulate every stakeholder of the company i.e. employees, customers, business partners, bankers who made IPO listing successful.

There has been a robust demand for pharma products across the globe and position of Indian Pharma companies has been elevated. Being a pharma chemical manufacturer, we have seen a strong traction among the pharma chemical products which showcase our market leadership across the globe. Due to softness in the Oil & Gas industry, we have seen lower revenue for Oilwell chemicals in Q2FY21. However, we have seen significant recovery from October 2020 onwards.

The operations of the company were impacted due to Covid-19 lockdown during Q1FY21. With the unlocking taking place, we were back on track and gathered momentum in Q2FY21. Pharma Chemical products HMDS & CMIC reported healthy growth for the quarter. Incase of CMIC, there has been huge volume growth coupled with price increase on YoY basis. For HMDS, the volume has remained stable with slight decrease in prices on YoY basis. Our profitability on absolute per tonne basis for HMDS remained stable.

We foresee business momentum to continue led by our recent capacity expansion of P2&P7 Plant, new product launch, land acquisition and product approval from government authorities for 44 products which includes 9 current products. Being a global leading manufacturer of pharmaceutical chemicals and a leading manufacturer in India of oilwell completion chemicals, we are in a strong position to encapsulate the upcoming opportunities buoyed by long standing relationship with customers.”

Recent Developments

✓ Commissioning of new Plants P7 and P2

- The company has commissioned 2 plants for manufacturing of HMDS with capacity of 1800 MTPA each. The plant P2 & P7 - P2 has flexibility to manufacture high purity HMDS and P7 has flexibility to manufacture CBC & DHT

✓ Launch of new products 4 CBC and 2,5 DHT

- **4 CBC:** 4 CBC is widely used in the pharmaceutical and agrochemical industry in the preparation of Pyrazinamide, a medication used to treat tuberculosis. It is also used for weed control in maize and sugarcane. Company executed our first sale of 4 CBC in Fiscal 2021
- **2,5 DHT:** 2,5 DHT is predominately used in the pharmaceutical industry in the preparation of and synthesis of substituted tetrahydrothiophene derivatives 2-amino-3-(arylsulfonyl) thiophenes, potential antiviral and antitumor agents. Company is in the process of commencing the manufacturing of 2,5 DHT

✓ Acquisition of land adjacent to the existing Manufacturing facility

- Company has acquired ~22,000 sqm of adjacent land to the existing manufacturing facility for the future expansion. Together with the existing land of ~29,000 sqm, the total land available with the Company increases to ~51,000 sqm

✓ Approval to manufacture 44 products from Government Authorities

- Company has successfully secured Environmental Clearance for manufacturing an aggregate of 44 products (including 9 current products) and increasing the quantity of products produced from 2,511 MT per month to 10,611 MT per month from State Level Environment Impact Assessment Authority, Government of Gujarat

About Chemcon Speciality Chemicals Ltd.

Incorporated in 1988, we are a manufacturer of specialized chemicals, such as HMDS & CMIC which are predominantly used in the pharmaceuticals industry and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry. In terms of production in the CY2019, we were the only manufacturer of HMDS in India and were the third largest manufacturer of HMDS worldwide. We were the largest manufacturer of CMIC in India and the second largest manufacturer of CMIC worldwide. Further, we were the only manufacturer of Zinc Bromide and the largest manufacturer of Calcium Bromide in India. We have 7 manufacturing facilities located at Manjusar near Vadodara in Gujarat. Our business presences are spread in USA, Germany, Italy, S. Korea, China, Japan, UAE, Serbia, Russia, Spain, Thailand and Malaysia. We are a ISO 9001:2015 and ISO 14001:2015 certified company for the “Manufacture and supply of pharmaceutical intermediates, silanes and oilfield chemicals”.

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Investor Relations Advisors :



Chemcon Speciality Chemicals Ltd.

CIN - U24231GJ1988PLC011652

Mr. Rajesh Gandhi – CFO,

Email ID: rajesh@cscpl.com

www.cscpl.com

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani

shrikant.sangani@sgapl.net

+91 79774 15681

www.sgapl.net